Fig. 1: A pooled mutant KRAS peptide vaccine given in combination with ipilimumab and nivolumab activates mKRAS-specific T cells in patients with resected PDAC.
From: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial
a Treatment schema for patients treated with mKRAS-VAX, a pool of 6 synthetic long mKRAS peptides in the adjuvant setting. Patients receive four doses of 0.3 mg peptide/dose with 5ug polyICLC during the priming phase followed by booster vaccines every 8 weeks. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) were given for the first four doses followed by Nivolumab (480 mg) maintenance doses every four weeks. Created in BioRender. Huff, A. (https://BioRender.com/1vglal1) (b) Clinical event timeline for each patient enrolled and vaccinated. c IFNγ ELISPOT assay of PMBCs collected at baseline and post-vaccination time points after restimulation with vehicle only control (unstimulated) or 2ug/mL control peptide or individual mKRAS long peptides overnight. Statistics of IFNγ spot forming units detected after each mKRAS peptide stimulation relative to control peptide are shown in Supplementary Table 5. Data are shown as mean (n = 3) and upper limit of SD.
